CDK9 and hematologic disorder: Moreover, the CDK9 inhibitor AZD4573 has shown effective antitumor activity through inhibition of CDK9, and AZD4573 is currently being evaluated in phase I clinical trial for patients with hematological malignancies (NCT03263637)103,104.